P46352 10th Annual Biosimilars Asia 2019 10th Annual Biosimilars Asia 2019
Download Brochure Request

Register your interest

Comments

Register your interest

Comments

10th Annual Biosimilars Asia 2019

14 – 16 May 2019, China

Book Now Download Brochure

LOCAL CHINA COMPANIES RATES AVAILABLE. 中国企业可享有独家优惠价!
SPECIAL GROUP RATES FOR 2 OR MORE. 2名及以上代表注册立享团队优惠价。SEE PRICING BELOW.

overview

The global biosimilars market is expected to reach $35 billion by 2030. Their uptake though faces considerable challenges in context to regulatory uncertainty, production complexity, interchangeability and competition. At IBC Asia’s 9th Annual Biosimilars Asia, top industry players will come together to explore tactics for overcoming hurdles unique to biosimilars in China, and globally. A focus on partnerships and commercial opportunities will be complemented by insights on disruptive technologies in manufacturing, commercialisation, risk management and pharma co-vigilance.

2018 Attendees List

View list >>

Key Highlights

  • 300+ Companies, 70+ speakers, 60+ Sessions
  • Unparalleled learning and targeted networking across three (3) co-located events
  • Assess global potential in the biosimilars market
  • Review the attractiveness of China as a continued investment destination
  • Developments in regulatory pathways and approvals in China
  • Examine advances in Innovation & Technology for Biosimilar Development
  • Optimise development strategies and production capabilities to ensure high product quality and stay ahead of competition
  • Preview latest equipment and technologies and hear from top vendors on how they are partnering with your peers

Choose your language

Part of

Biopharma Development & Production >>

Co-Located Events

Biosimilars Asia >>
Cell Line Development and Engineering >>
Biomanufacturing >>

agenda

8:00 am

Registration Opens and Morning Coffee

BIOPHARMA DEVELOPMENT AND PRODUCTION 2018 OPENING PLENARY SESSIONS

9:00 am

Chairperson’s Opening Remarks

Dr. Ming Wang, President and Chief Executive Officer, Phanes Biopharmaceuticals, China

10:10 am

[Industry Address] Global M&A Trends and Deal Flow in the Outsourced Pharma Manufacturing Services Sector

Andrew Huntley, Senior Managing Director, BDA Partners, UK

10:50 am

Morning Networking and Refreshment Break

END OF OPENING PLENARY AND 9TH BIOSIMILARS ASIA CONFERENCE COMMENCES

11:10 am

Chairperson’s Opening Remarks

Dr. Ming Wang, President and Chief Executive Officer, Phanes Biopharmaceuticals, China

CHINA’S BIOSIMILARS MARKET 中国的生物仿制药市场

11:15 am

Nutritional Levers for Biosimilarity

Dr. Ryan Karcher, Senior R&D Scientist & Team Lead, Merck, USA

11:40 am

The Importance of Media and Supplements in Two Biosimilar CHO Cell Lines

Henry Zhang, APAC Technical Application Representative – Cell Nutrition, Kerry Inc., China

12:30 pm

Networking Lunch

1:30 pm

China Market Insight: Market Growth and Opportunities in Therapeutic Biosimilars 中国市场洞察:治疗性生物仿制药的市场成长和机会

Xiao Zhi Hua, Chief Executive Officer, OPM Biosciences, China

2:00 pm

Managing Costs and Technology Adoption in Biosimilar Development 生物仿制药临床试验解读-生物仿制药研发的成本管理和技术选用

Dr. Manfred Weiler, Senior Vice President, Medical & Scientific Strategy, Syneos Health, UK

2:30 pm

Biosimilars Development in China: Challenges in Bevacizumab Clinical Trial Design

Dr. Jacqueline Ming Liu, Vice President, TOT Biopharma, China

3:00 pm

Afternoon Networking & Refreshment Break

QUALITY AND SIMILARITY ASSESSMENT

3:30 pm

Biosimilar Clinical Materials: Changes and Comparability 生物仿制药临床材料:变化与可比性

Dr Qiwei Wu, Ph.D, Vice President of Process Development and Manufacturing, Livzon Mabpharma

4:10 pm

Fireside Chat: Analytical and Quality Assessment of Biosimilars 炉边闲谈: 生物仿制药的分析和质量评估

Dr. Ming Wang, President and Chief Executive Officer, Phanes Biopharmaceuticals, China

Dr Amy Hong Que, Vice President - Quality, Innovent Biologics

4:40 pm

End of Day Round-up Q&A session

5:20 pm

Chairperson’s Summary and End of Main Conference Day One followed by Networking Cocktail

9:00 am

Chairperson’s Opening Remarks

Dr. Alvin Luk, Senior Vice President and Chief Medical Officer, Shanghai Henlius Biotech, Inc., China

GOING GLOBAL AND PARTNERSHIPS 走向国际,寻求合作

9:10 am

Opening Address: Key Learnings from a Global Perspective How to Unlock the Full Potential of Biosimiliars - Learnings from EU on Access and Procurement 开场致辞:全球角度总结—如何解锁生物仿制药的全部潜能—EU市场准入和采购的经验学习

Prof. Dr. Florian Turk, Head Global Payor Marketing, Sales and Relations, Sandoz Biopharmaceuticals Sandoz International GmbH, Germany

9:40 am

Case Study: Global Development Strategy on Biosimilars: How to Win in the International Space 案例研究:生物仿制药的全球发展策略:如何在国际市场取得领先地位

Pearl Fong, Associate Vice President, Division of Project Development, Mycenax Biotech Inc., Taiwan

10:10 am

Biopharma’s Case Study: Perspective on Biosimilars Market Development and Partnerships

Bryan Kim, Vice President of Business Development, Samsung Bioepis, Korea

10:40 am

Morning Networking & Refreshment Break

SAFETY AND EFFICACY 安全性和效能

11:10 am

A Biopharma Solution for Automated Glycan Characterization

Dr. Sven Bahrke, Senior Director Cooperations, Glycotope GmBH

11:40 am

The Long and Winding Road: Operational Challenges for Biosimilar Clinical Trials

Dr. Xin Zhang, Vice President of Global Clinical Operations and Affairs, Shanghai Henlius Biotech, Inc., China

12:10 pm

Networking Lunch

COMMERCIALISATION OF BIOSIMILARS 生物仿制药的商业化

1:10 pm

Biopharma’s Case Study: Remsima® success story and strategy to overcome hurdles, move into Mainstream 生物制药的案例研究:Remsima®的成功故事——跨越障碍,成为主流品牌

MinSeob Lee, Team Leader of R&D CMC/PM, Celltrion R&D, Korea

2:00 pm

Commercialization Practicality: CFDA’s Requirement on Biosimilar Application and RA Operation Support Model

Eric Liu, China Biosimilars Regulation Publishing Manager, Pfizer, China

2:50 pm

Applying High Throughput Process Development Platform to Develop Downstream Process for Clinical Manufacturing

Jiang Junjun, Assistant Director, WuXi Biologics, China

3:10 pm

Fireside Chat: Product Pipelines and Investments

3:40 pm

Afternoon Networking and Refreshment Break

BIOPHARMA DEVELOPMENT & PRODUCTION 2018 CLOSING PLENARY SESSIONS

5:00 pm

Chairperson’s Summary of the Day and End of Conference

9:00 am

The rapid development of antibody drugs in recent years has received extensive attention from pharmaceutical and biotechnology companies. More and more “blockbusters” are facing “patent cliff”, which makes the competition of biosimilar drugs intensified. Biologic drugs are highly complex molecules produced by living cells through a multistep manufacturing process. The key characteristics of these molecules, known as critical quality attributes (CQAs), can vary based on post-translational modifications that occur in the cellular environment or during the manufacturing process. The CQAs of biosimilars must be characterized and systematically compared with reference drug to ensure bio-similarity. The close matching of the originator fingerprint is the foundation of the biosimilarity. Quality control & analysis should be considered in whole process of development. The talk will give an overview introduction of integration of process development and protein analytics to improve biosimilarity.

Accord to Quality by Design principles, quality control should cover the whole process of protein drug preclinical development, including cell line development (CLD), upstream and downstream process development (PD), and CMC. In the early stage of biosimilar development, cell growth and titer are typically used as the criteria for clone selection and process optimization, and multiple protein quality contributes are not monitored. In order to confirm and improve quality similarity, extended protein characterization should be carried out, and the critical quality contributes (CQAs) of each process should be determined and analyzed. In this slides, the strategies and technologies for extended protein characterization are summarized, and case studies of CQAs control in CLD and PD are presented..

Key Considerations in PK of Biosimilar Development

Lihou Dong, Senior Director, United-Power Pharma

1:00 pm

End of workshop

pricing

Packages Price
2 Day Conference - International Companies, Global HQ Located Outside ChinaUS $1895US $1695Early BirdEarly Bird
2 Day Conference - Local China CompaniesUS $977US $827Early BirdEarly Bird
Group Rate of 2 or more delegates - International Companies, Global HQ Located Outside ChinaUS $1495Early Bird
Group of 2 or more delegates - Local China CompaniesUS $752Early Bird
Group of 4 or more delegates - Local China CompaniesUS $676Early Bird
Group Rate of 4 or more delegates - International Companies, Global HQ Located Outside ChinaUS $1295Early Bird
Extras Price
Pre Conference Workshop - International Companies, Global HQ Located Outside China US $300
Pre Conference Workshop - Local China Companies US $150
  • Multiple Bookings Discount pricing is applicable to groups of 2 or more delegates from the same organisation registering for the same event, at the same time.
  • Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR group rate.
  • All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
  • All delegates from Singapore-based companies are required to pay an additional 7% GST (SINGAPORE EVENTS ONLY)

Sponsorship

Partnership and Profile Building Opportunities are Now Available!
Contact us today to find out how you can position your company as a market leader at this event, and to explore the range of branding and marketing opportunities available.

View Sponsors and Exhibitors profile >>

VIP Programme

Become a VIP!
IBC Asia’s VIP Programme is an invitation only based network of the absolute top decision makers across specific industries. Our VIPs get an exclusively designed and tailored programme that enables them to network, indulge and enjoy, whilst experiencing a premium service for the duration of this event.

Dedicated to helping you find the most effective way of engaging with professionals and industry solution providers at our event, and scheduled alongside the main event line-up, it gives you an opportunity to glean benefits from the conference as well, and ensures that you get the most of your time on site with us.

Benefits of becoming a VIP:

  • 1-2-1 Meeting Service (Pre-scheduling meetings with your peers, speakers and other participants you may want to meet)
  • Closed Door Think Tank (An invitation-only forum headlined by an exclusive keynote address)
  • The VIP Lounge
  • Opening Ceremony (Access priority seats and be the first to engage with key speakers and other top decision makers)
  • Your Interview, Promoted Exclusively

A personalized VIP agenda will be sent to you via email upon receiving the confirmation of your registration.

To find out more, please contact:
Angeline Tan, VIP Relations Manager
Email: Angeline.Tan.SG1@ibcasia.com.sg
Phone: +65 6508 2874

Download VIP Programme brochure »

speakers

Dr. Ming Wang

President and Chief Executive Officer, Phanes Biopharmaceuticals, China

Xiao Zhi Hua

Chief Executive Officer, OPM Biosciences, China

Xu Wei

Vice President, Manufacturing, Innovent Biologics, China

Jerry Yang

SVP, Process & Product Development, Hangzhou JUST Biotherapeutics Co., Ltd., China

Dr Jun Liu

Vice President, TOT Biopharma, China

Yanshan Huang

Chief Executive Officer, DOER Biologics, China

Andrew Huntley

Senior Managing Director, BDA Partners, UK

Dr. Ryan Karcher

Senior R&D Scientist & Team Lead, Merck, USA

Henry Zhang

APAC Technical Application Representative – Cell Nutrition, Kerry Inc., China

Dr. Scott Liu

President and CEO, Shanghai Henlius Biotech Inc., China

Dr. Manfred Weiler

Senior Vice President, Medical & Scientific Strategy, Syneos Health, UK

Dr. Jacqueline Ming Liu

Vice President, TOT Biopharma, China

Dr Qiwei Wu

Ph.D, Vice President of Process Development and Manufacturing, Livzon Mabpharma

Dr Amy Hong Que

Vice President - Quality, Innovent Biologics

Dr. Alvin Luk

Senior Vice President and Chief Medical Officer, Shanghai Henlius Biotech, Inc., China

Prof. Dr. Florian Turk

Head Global Payor Marketing, Sales and Relations, Sandoz Biopharmaceuticals Sandoz International GmbH, Germany

Pearl Fong

Associate Vice President, Division of Project Development, Mycenax Biotech Inc., Taiwan

Bryan Kim

Vice President of Business Development, Samsung Bioepis, Korea

Dr. Sven Bahrke

Senior Director Cooperations, Glycotope GmBH

Dr. Xin Zhang

Vice President of Global Clinical Operations and Affairs, Shanghai Henlius Biotech, Inc., China

MinSeob Lee

Team Leader of R&D CMC/PM, Celltrion R&D, Korea

Eric Liu

China Biosimilars Regulation Publishing Manager, Pfizer, China

Jiang Junjun

Assistant Director, WuXi Biologics, China

Yun Kang

Vice President of Manufacturing, Generon Beijing, China

Zheru Zhang

President, I-Mab Biopharma, China

Shaoqing Yang

Vice President, Zhejiang Doer Biologics Co.

Yunfen He

Senior Director, OPM Biosciences

Zhigui Zhou

Director, OPM Biosciences

Lihou Dong

Senior Director, United-Power Pharma

when & where

14 - 16 May 2019

contact

Still have a question?

Speaking Opportunities
Sheralin See
+65-6508 2442
 
sheralin.seekaili@ibcasia.com.sg

Sponsorship Opportunities
Yvonne Leong
+65 6508 2489

Yvonne.Leong@ibcasia.com.sg

Media & Association Partnership Opportunities
June Tan
+65 6508 2465
June.Tan@ibcasia.com.sg

STAY UPDATED ON OUR NEWS & EVENTS

IBC Asia is Singapore's leading event organiser. We conceive, develop and promote our own B2B industry conferences and corporate training courses, and offer tailored managed event solutions.

Find out more